TKTeele Kuusk

Teele Kuusk

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Teele Kuusk has a total of 99 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Oligoprogressive renal cell carcinoma: What is the role of surgery?

    by Chiara Re, William H.J. Ince, Leo Bickley, James P. Blackmur, Mouhamad H. Ismail, Justicia Kyeremeh, Teele Kuusk, Eva Mendes Serrao, James O. Jones, Grant D. Stewart

    Objective: To provide an overview of the biological mechanism and pattern of oligoprogression in renal cell carcinoma (RCC) and the most updated role of surgery in this setting, highlighting scientific gaps and informing future implications. Methods: A non‐systematic search of PubMed/MEDLINE was performed in August 2025 including guidelines, reviews, and original studies. Additional sources were identified through manual reference screening. Results: Oligoprogression in RCC likely arises from clonal evolution dynamics, with spatially confined subclone mutations and microenvironmental niches yielding differential responses to treatment. Complete metastasectomy may offer a survival benefit, spare patients toxic side effects of systemic therapy, and offers the possibility of histopathological and molecular characterisation of residual disease. Surgery is also particularly important in delayed cytoreductive nephrectomy as the site of oligoprogression. However, this must be weighed against non‐negligible surgical morbidity and complication rates. International guidelines recognise the role of surgical resection in the metastatic setting but emphasise low evidence levels and careful patient selection requirements. Conclusion: Limited evidence derived from the oligometastatic context constrains optimal patient selection and timing strategies in oligoprogressive RCC. Following the establishment of consensus over definitions and research gaps, future research integrating molecular biomarkers, novel imaging tracers, and multicentre collaborative studies will be essential to develop evidence‐based surgical management protocols for this increasingly common clinical scenario.


  • Open Access

    Sentinel lymph node staging in urological cancer surgery: advances in imaging, intra‐operative detection and translational research

    by Erik J. van Gennep, Gijs H. KleinJan, Teele Kuusk, Rick W.A. Verdijk, Esther M.K. Wit, Bas W.G. van Rhijn, Axel Bex, Laura S. Mertens

    Objectives: To review the clinical utility, outcome and possible future applications of sentinel lymph node biopsy (SLNB) in penile cancer (PeC), bladder cancer (BCa), prostate cancer (PCa), testicular cancer (TCa) and renal cell carcinoma (RCC), focusing in particular on current SLNB standards and exploring advancements in imaging agents, intra‐operative detection, surgical navigation, and the potential application of SLNB in translational and clinical research. Methods: A literature search was conducted in PubMed and EMBASE for studies published between 2000 and 2024, providing a narrative review of SLNB in oncological urology. Results: In PeC, SLNB offers a lower adverse event rate compared to inguinal lymph node (LN) dissection, while maintaining high detection rates and acceptable sensitivity (92%–96%) for identifying inguinal LN metastases. Similarly, in PCa, SLNB achieves a sensitivity of 95%, potentially reinforcing its role in nodal staging and guiding personalised treatment strategies. For RCC, BCa and TCa, SLNB is currently under investigation in trials. In RCC, detection rates seem acceptable; however, in BCa and TCa, detection rates and false‐negative rates vary, limiting its clinical usefulness. Contemporary approaches utilise various radiotracers, (fluorescent) dyes, and hybrid tracers for SLNB. Ongoing research refines tumour‐targeted LN detection, including prostate‐specific membrane antigen targeting in PCa, potential c‐MET targeting in PeC, and 89 Zr‐girentuximab in RCC. Conclusion: The use of SLNB has transformed nodal staging in PeC, influencing treatment decisions and reducing morbidity in patients undergoing surgery. In other urological malignancies, it has not yet established itself as a standard tool for nodal staging. Its impact on survival, quality of life, and translational research remains to be determined.


  • Perioperative impact of body mass index on upper urinary tract and renal robot-assisted surgery: a single high-volume centre experience

    by Sergio Fernandez-Pello, Neeta Verma, Teele Kuusk, Aleksandra Berezowska, Faiz Mumtaz, Prasad Patki, Maxine Tran, Ravi Barod, Axel Bex

    To assess the impact of body mass index (BMI) on peri-operative outcomes of kidney and upper tract robot-assisted surgery. Medical audit of patients who underwent robot-assisted kidney and upper tract cancer surgery at a single institution between 2017 and 2019, categorized on BMI into obese patients with a BMI ≥ 30 kg/m2 and a control group with BMI < 25 kg/m2. Patient and tumour characteristics, surgery time, intraoperative blood loss, intraoperative adverse events (AE) according to the European Association of Urology Intraoperative Adverse Incidents Classification (EAUiaiC), conversion- to-open/radical rate as well as 30-day postoperative AE according to Clavien-Dindo (CD) and length of inpatient stay were analyzed. 366 patients were identified, 141 with a BMI < 25 (normal-weight) and 225 BMI ≥ 30 (obesity). There were no significant differences between the groups in terms of age, gender, comorbidities, tumour size, TNM stage and type of surgery. Obese patients had a higher estimated blood loss (198.05 ml), surgery time (171.75 min), intraoperative AE (all grades) (14.67%, 95% CI (0.10–0.19) as well as adherent perinephric fat (APF) (14.22%, 95% CI (0.09–0.19)) in contrast to the control group (86.85 ml, 148.29 min, 7.04% and 2.12%, respectively). Hospital stay, major intraoperative AE (≥ 3) and major postoperative AE (CD > 2) distributed equally between groups. Robotic kidney and upper tract surgery in obese patients showed an increase in surgery time and blood loss potentially related to APF. However, obesity was not associated with conversion to open surgery or radical nephrectomy in nephron-sparing procedures, length of stay, major intraoperative AE or postoperative complications.


  • European Association of Urology COVID intermediate prioritisation group is poorly predictive of pathological high-risk among patients with renal tumours

    by P. Satish, T. Kuusk, N. Campain, Y. Abu-Ghanem, J. Neves, R. Barod, S. El-Sheikh, F. Mumtaz, P. Patki, M. Tran, et al.

  • Open Access

    Impact of the first surge of the COVID‐19 pandemic on a tertiary referral centre for kidney cancer

    by Teele Kuusk, David Cullen, Joana Briosa Neves, Nicholas Campain, Ravi Barod, Ekaterini Boleti, Soha El‐Sheihk, Lee Grant, John Kelly, Marta Marchetti, et al.

    Objective: To analyse the impact of the COVID‐19 pandemic on a centralized specialist kidney cancer care pathway. Materials and Methods: We conducted a retrospective analysis of patient and pathway characteristics including prioritization strategies at the Specialist Centre for Kidney Cancer located at the Royal Free London NHS Foundation Trust (RFH) before and during the surge of COVID‐19. Results: On 18 March 2020 all elective surgery was halted at RFH to redeploy resources and staff for the COVID‐19 surge. Prioritizing of patients according to European Association of Urology guidance was introduced. Clinics and the specialist multidisciplinary team (SMDT) meetings were maintained with physical distancing, kidney surgery was moved to a COVID‐protected site, and infection prevention measurements were enforced. During the 7 weeks of lockdown (23 March to 10 May 2020), 234 cases were discussed at the SMDT meetings, 53% compared to the 446 cases discussed in the 7 weeks pre‐lockdown. The reduction in referrals was more pronounced for small and asymptomatic renal masses. Of 62 low‐priority cancer patients, 27 (43.5%) were deferred. Only one (4%) COVID‐19 infection occurred postoperatively, and the patient made a full recovery. No increase in clinical or pathological upstaging could be detected in patients who underwent deferred surgery compared to pre‐COVID practice. Conclusion: The first surge of the COVID‐19 pandemic severely impacted diagnosis, referral and treatment of kidney cancer at a tertiary referral centre. With a policy of prioritization and COVID‐protected pathways, capacity for time‐sensitive oncological interventions was maintained and no immediate clinical harm was observed.


  • Open Access

    European Association of Urology COVID intermediate prioritisation group is poorly predictive of pathological high- risk among patients with renal tumours

    by Pranav Satish, Teele Kuusk, Nick Campain, Yasmin Abu-Ghanem, Joana Neves, Ravi Barod, Soha El-Sheikh, Faiz Mumtaz, Prasad Patki, Maxine Tran, et al.

    Introduction The purpose of prioritisation is to minimise harm while safeguarding access to health care in times of reduced resources. The EAU Guideline Office Rapid Reaction Group (GORRG) issued priority recommendations during the COVID-19 pandemic. We evaluated if the clinical prioritisation for suspected renal cell carcinoma (RCC) planned for surgery matched final pathological risk. Methods From 23 March 2020 until 10 October 2020, patients with suspected RCC were prioritised according to GORGG recommendations. To increase statistical power, GORGG prioritisation was also retrospectively assigned to pre-lockdown RCC surgical cases. The priority group was assessed according to GORGG guidelines, and postoperative risk was assessed according to 2003 Leibovich scores. We evaluated concordance between GORGG prioritisation and post-operative risk, and if stratification could be further improved by subgrouping of size. Results 351 patients with suspected RCC were prioritised and underwent surgery. The intermediate priority group showed poor concordance, with 25.7% and 16.4% being pathological low and high risk, respectively. The low priority group harboured 14.9% intermediate and 1.06% high risk RCC. Within the EAU intermediate group, 34.2% of cT1b tumours were low risk, and 32.3% of cT2a tumours high risk. Analysing at 1 cm increments, 45.1% of 4-5cm tumours were low risk. Conclusions The recommended prioritisation system can be error prone and should be prudently applied based on the centre’s needs. Particularly amongst the intermediate group, centres with clinical capacity should not defer intervention of cT2a tumours for longer than absolutely necessary and in severely limited resources may consider intermediate priority tumours < 5cm as low priority.

  • Outcome after resection of occult and non-occult lymph node metastases at the time of nephrectomy

    by Teele Kuusk, Tobias Klatte, Patricia Zondervan, Brunolf Lagerveld, Niels Graafland, Kees Hendricksen, Umberto Capitanio, Andrea Minervini, Grant D. Stewart, Borje Ljungberg, et al.

    Purpose There is sparse evidence on outcomes of resected occult LN metastases at the time of nephrectomy (synchronous disease). We sought to analyse a large international cohort of patients and to identify clinico-pathological predictors of long-term survival. Materials and methods We collected data of consecutive patients who underwent nephrectomy and LND for Tany cN0-1pN1 and cM0-1 RCC at 7 referral centres between 1988 and 2019. Patients were stratified into four clinico-pathological groups: (1) cN0cM0-pN1, (2) cN1cM0-pN1(limited, 1–3 positive nodes), (3) cN1cM0-pN1(extensive, > 3 positive nodes), and (4) cM1-pN1. Overall survival (OS) was estimated using the Kaplan–Meier method, and associations with all-cause mortality (ACM) were evaluated using Cox models with multiple imputations. Results Of the 4370 patients with LND, 292 patients with pN1 disease were analysed. Median follow-up was 62 months, during which 171 patients died. Median OS was 21 months (95% CI 17–30 months) and the 5-year OS rate was 24% (95% CI 18–31%). Patients with cN0cM0-pN1 disease had a median OS of 57 months and a 5-year OS rate of 43%. 5-year OS (median OS) decreased to 29% (33 months) in cN1cM0-pN1(limited) and to 23% (23 months) in cN1cM0-pN1(extensive) patients. Those with cM1-pN1 disease had the worst prognosis, with a 5-year OS rate of 13% (9 months). On multivariable analysis, age (p = 0.034), tumour size (p = 0.02), grade (p = 0.02) and clinico-pathological group (p < 0.05) were significant predictors of ACM. Conclusion Depending on clinico-pathological group, grade and tumour size, 5-year survival of patients with LN metastases varies from 13 to 43%. Patients with resected occult lymph node involvement (cN0/pN1 cM0) have the best prognosis with a considerable chance of long-term survival.


  • Open Access

    An analysis of SPECT/CT non-visualization of sentinel lymph nodes in renal tumors

    by Teele Kuusk, Maarten L. Donswijk, Renato A. Valdés Olmos, Roderick E. De Bruijn, Oscar R. Brouwer, Kees Hendricksen, Simon Horenblas, Katarzyna Jóźwiak, Warner Prevoo, Henk G. Van Der Poel, et al.

    Sentinel lymph node biopsy (SLNB) after intratumoral injection of 99mTc labeled nanocolloid and imaging with scintigraphy and SPECT/CT in renal tumors is feasible. However, sentinel lymph node (SN) non-detection rate with scintigraphy and SPECT/CT is high. The aim of the study was to determine factors affecting non-visualization (NV) of SN imaging in renal tumors. Seventy-eight patients with cT1–3 renal tumors received intratumoral injection of 225 MBq 99mTc-labeled nanocolloid 1 day before (partial) nephrectomy. Radiotracer injection was followed by anterioposterior and lateral scintigraphy in combination with SPECT/CT 20 min and 2–4 h after. Surgical treatment of the tumor with sentinel lymph node biopsy by aid of γ-probe and-camera was performed the next day. Scintigraphy and SPECT/CT images were evaluated and patient, tumor, and procedure characteristics were collected for 73 eligible patients used in uni- and multivariable analysis of a potential association with NV. A total of 80 (mean 1.1, IQR 0–2, max 6) sentinel lymph nodes in 46 patients were detected with scintigraphy and SPECT/CT. Preoperative visualization rate and intraoperative detection rate was 63% [95% CI 50–73%] and 61% [95% CI 49–72%], respectively. In uni- and multivariable analysis, the only factor associated with non-visualization was age, showing higher odds of non-visualization with higher age. Our study demonstrated that non-visualization of SNs in renal tumors is relatively high and is associated with patient age. Furthermore, kidneys and also its tumors are highly vascularized which may cause a wash-out effect that could be identified with decreased kidney-liver ratios. However, in our data, the effect was statistically inconclusive. Further studies are needed to improve visualization and standardize the procedure of SLNB in renal tumors. The percentage of NV limits the use of SLNB for research and clinical purposes in renal cancer.


  • Outcome of sentinel lymph node biopsy in patients with clinically non-metastatic renal cell carcinoma

    by Teele Kuusk, Roderick De Bruijn, Oscar R Brouwer, Jeroen De Jong, Maarten Donswijk, Kees Hendricksen, Simon Horenblas, Katarzyna Jóźwiak, Warner Prevoo, Renato A Valdés Olmos, et al.

    Objective: To investigate the rate of occult SN metastases, oncological outcome, and association of recurrence with the pattern of lymphatic tumour drainage in RCC. Materials and methods: A pooled RCC sub-group analysis was conducted of secondary endpoints from a published feasibility and a phase II prospective single-arm SN study to investigate oncological outcome. Patients with cT1-3 (99m nanocolloid, pre-operative imaging of SNs with SPECT/CT was followed by (partial) nephrectomy with SN and regional lymph node dissection using a γ-probe. The patients were followed with a risk-adapted surveillance programme. Endpoints of the studies were analysed using Cox proportional hazard models. Results: Sixty-six RCC patients were included. Two patients (3%, 95% CI =0.5–11%) had occult SN metastases and remained free of disease at 57 and 72 months. Ten patients (15%, 95% CI =7–26%) developed recurrences, and four (6%, 95% CI =2.3–14.5%) had died of disease at a median follow-up of 57 months (IQR =18–72 months). Occurrence of distant metachronous metastases were associated with tumour size (HR =1.39, p = 0.02), pT stage (HR =6.83, p < 0.01 for comparison T1 vs T3/4), Grade 3/4 (HR =8.38, p = 0.05 for comparison 1/2 vs 3/4) and interaortocaval sentinel lymph node location (HR =10.52, p = 0.03 for comparison yes vs no). Conclusions: The rate of occult metastatic SN is low, but long disease-free survival (DFS) was observed in two patients with occult SN metastases. We hypothesize an interaortocaval lymphatic route in thoracic recurrences. Evaluation of the prognostic and therapeutic role of sentinel lymph node biopsy (SLNB) requires a clinical trial in high-risk RCC.